Bronchogen

Bronchogen (Ala-Glu-Asp-Leu) is the respiratory-associated member of a family of synthetic short peptides developed within the Khavinson peptide-bioregulator research program at the St. Petersburg Institute of Bioregulation and Gerontology, which produced defined-sequence peptides by directed synthesis modeled on motifs identified in tissue peptide extracts. The AEDL sequence and its synthetic characterization — molecular formula C18H30N4O9; molecular weight 446.45 g/mol; documented as an acetate salt — are recorded in US Patent 7,625,870 (Khavinson, Ryzhak, Grigoriev & Ryadnova, 2009), which describes the experimental respiratory model systems in which the tetrapeptide was studied, including acute bacterial pneumonia, bleomycin-induced fibrosis, hyperoxic injury, and organotypic lung tissue-culture explants in rats. The broader framework positing that short peptides of 2–7 residues may penetrate cells, enter the nucleus, and interact with DNA to associate with gene-expression changes is reviewed by Vanyushin & Khavinson (2016) and across the class in the systematic review by Khavinson et al. (2021).

The most sequence-specific applied work places Bronchogen in bronchial and pulmonary cell and tissue models. Khavinson et al. (2014, Lung) characterized Ki67, Mcl-1, p53, CD79, and NOS-3 protein levels across serial passages of human bronchial epithelial cell cultures alongside expression profiling of bronchial-differentiation factors NKX2-1, SCGB1A1, SCGB3A2, FOXA1, and FOXA2 and mucin/surfactant genes MUC4, MUC5AC, and SFTPA1; the study also included spectrophotometric, viscometric, and circular-dichroism examination of the peptide–DNA interaction. In a rodent preclinical system, Kuzubova et al. (2015, Bulletin of Experimental Biology and Medicine) used a 60-day intermittent nitrogen dioxide–exposure protocol in rats as a model of obstructive lung pathology and assessed bronchial-epithelial morphology endpoints — goblet-cell hyperplasia, squamous metaplasia, lymphocytic infiltration, and ciliated-cell status — and secretory immunoglobulin A as a mucosal marker. These are cell-culture and animal-model measurement contexts and not human or in vivo functional outcomes.

A separate strand of biophysical work characterizes the AEDL–nucleic acid and AEDL–chromatin interactions in isolation. Monaselidze et al. (2011, Bulletin of Experimental Biology and Medicine) — the study whose title explicitly names "the peptide bronchogen" — applied differential scanning microcalorimetry to measure DNA melting thermodynamics across a range of peptide-to-DNA base-pair molar ratios, examining interactions with calf thymus and mouse liver DNA and characterizing the interaction as a DNA-stabilizing one that was non-specific to particular base pairs. Fedoreyeva, Vanyushin & Baranova (2020, AIMS Biophysics) examined chromatin-conformation changes associated with AEDL exposure, reporting binding to linker histone H1 and core histone H3 and an associated reduction of condensed-chromatin domains. Nuclear penetration of fluorescently labeled short peptides in the Khavinson class was examined in cultured cells by Fedoreyeva, Kireev, Khavinson & Vanyushin (2011, Biochemistry (Moscow)) as a mechanistic entry point for the proposed nucleus-targeting model, and docking-based modeling (Khavinson, Lin'kova & Tarnovskaya, 2016) places short peptides of this class at gene-promoter tetranucleotide binding sites.

Computational work has examined the AEDL tetrapeptide as a discrete molecular object. A molecular-dynamics study (Sokolova et al., 2025, WSEAS Transactions on Biology and Biomedicine) simulated the interaction of AEDL molecules with lysine-based dendrimer nanocontainers bearing arginine–histidine spacers at two pH values, examining the number of peptide molecules carried, hydrogen-bond formation, and depth of penetration into the carrier. Broader structural and biophysical work on the short-peptide class — DNA double-strand thermodynamic melting behavior after geroprotective tetrapeptide binding (Khavinson, Solovyov & Shataeva, 2008) and molecular-mechanics docking of short cell-penetrating peptides at promoter DNA sites (Khavinson, Tarnovskaya et al., 2013) — frames the general mechanistic hypothesis examined for AEDL rather than establishing an AEDL-specific bronchial mechanism.

The proposed DNA-interaction mechanism has been examined in plant model systems as part of a broader argument for cross-kingdom conservation. Lazareva et al. (2025, International Journal of Molecular Sciences) characterized metabolism and autophagy markers — including the autophagy marker ATG8, cytochrome c release, and TUNEL-detected DNA strand breaks — in root cells of Nicotiana tabacum exposed to the AEDL tetrapeptide, and an earlier study by Fedoreyeva et al. (2017, Biochemistry (Moscow)) examined AEDL alongside related short peptides for associations with expression of CLE, KNOX1, and GRF gene families in the same plant model system. These comparative studies are cited by the originating research group as supporting a conserved peptide–DNA interaction mechanism; they do not independently establish relevance in mammalian or human systems.

The published Bronchogen-specific literature is small and concentrated almost entirely within the Khavinson research network and affiliated laboratories — notably the Bulletin of Experimental Biology and Medicine and associated Russian-language venues. The naming is not fully standardized: the same residue composition appears in the primary literature as both Ala-Glu-Asp-Leu (AEDL) and Ala-Asp-Glu-Leu (ADEL), and several mechanistic findings derive from peptide-panel studies where the tetrapeptide appears alongside other short bioregulators rather than being examined in isolation. No registered human clinical trials specific to the defined tetrapeptide were identified in ClinicalTrials.gov or the indexed literature, and independent replication of the bronchial-specific findings outside this network is limited. These constraints should be weighed when interpreting the mechanistic hypotheses.